<scp>CCAAT</scp>/enhancer‐binding protein β overexpression alleviates myocardial remodelling by regulating angiotensin‐converting enzyme‐2 expression in diabetes

Yuanyuan Tie, Chungang Zhai, Ya Zhang, Xiaoteng Qin, Fangpu Yu, Hongxuan Li, Meirong Shan, Cheng ZhangJournal of Cellular and Molecular Medicine 2017 · DOI

TL;DR

This study reveals that boosting the expression of a transcription factor called C/EBPβ can significantly improve heart function in diabetic mice by upregulating ACE2, a key enzyme in the renin-angiotensin system. This suggests C/EBPβ could be a novel therapeutic target for diabetic cardiomyopathy, potentially offering greater benefits than current treatments like valsartan.

What Problem Does This Paper Address?

Diabetic cardiomyopathy (DCM) is a serious complication of diabetes that leads to heart remodeling and failure, independent of other cardiovascular risk factors. A major pathological mechanism in DCM is myocardial fibrosis (scarring of the heart muscle) and cardiomyocyte apoptosis (programmed cell death). The renin-angiotensin system (RAS) plays a crucial role in this process, with a balance between the ACE-Angiotensin II (Ang II) axis and the ACE2-Angiotensin-(1-7) (Ang(1-7)) axis being critical for heart health. In DCM, this balance is disrupted, often favoring the pro-fibrotic and pro-apoptotic Ang II pathway. While ACE2 is known to counteract these harmful effects, the mechanisms that regulate its expression in DCM are not fully understood. This paper investigates the role of the transcription factor C/EBPβ in regulating ACE2 and mitigating DCM, aiming to uncover a new therapeutic strategy.

Methods

The researchers employed a multi-pronged approach:

  • Animal Model: A type 1 diabetic mouse model was created using streptozotocin (STZ) injection. These diabetic mice were then treated with lentiviruses to either overexpress C/EBPβ or silence its expression (sh-C/EBPβ), or with valsartan, a known RAS inhibitor.
  • In Vitro Studies: Primary cardiac fibroblasts (CFs) and H9C2 cardiomyocytes were exposed to high glucose (HG) conditions to mimic the diabetic environment. These cells were also treated with lentiviruses for C/EBPβ manipulation or valsartan.
  • Echocardiography: This non-invasive technique was used to assess cardiac function and dimensions (e.g., ejection fraction, wall thickness, chamber size) in the treated mice.
  • Histology and Immunohistochemistry: Heart tissues were stained to visualize and quantify collagen deposition (fibrosis) and the expression of key proteins like C/EBPβ, ACE2, and TGF-β1.
  • Biochemical Assays: ELISA was used to measure levels of Ang II and Ang(1-7) in both heart tissue and serum. Serum levels of inflammatory markers (IL-6, MCP-1) and matrix metalloproteinases (MMPs) were also assessed.
  • Western Blotting: This technique was used to quantify the protein levels of various molecules involved in fibrosis, apoptosis, and the RAS pathway (e.g., collagen I & III, TGF-β1, Bax, Bcl-2, AT1R, AT2R, MasR, ACE, ACE2, C/EBPβ).
  • Chromatin Immunoprecipitation (ChIP) Assay: This crucial assay was performed to determine if C/EBPβ directly binds to the ACE2 promoter, providing evidence for a direct regulatory mechanism.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from animal models and cell cultures.

Key Insights and Ideas

  • C/EBPβ is Downregulated in Diabetes: The study found that C/EBPβ expression is significantly reduced in both diabetic mouse hearts and high-glucose-treated cardiac cells. This suggests that a loss of C/EBPβ function contributes to the development of diabetic cardiomyopathy.
  • C/EBPβ Overexpression Protects the Heart: Boosting C/EBPβ levels in diabetic mice and cells effectively attenuated cardiac fibrosis, reduced cardiomyocyte apoptosis, and improved overall cardiac function. This highlights C/EBPβ's protective role.
  • ACE2 is a Key Mediator: The protective effects of C/EBPβ were strongly linked to the upregulation of ACE2 expression. This suggests that C/EBPβ exerts its beneficial effects, at least in part, by increasing ACE2.
  • Direct Binding to ACE2 Promoter: The ChIP assay provided direct evidence that C/EBPβ binds to the ACE2 promoter, acting as a transcription factor to regulate ACE2 gene expression. This is a novel mechanistic insight.
  • Valsartan vs. C/EBPβ: While valsartan, a standard treatment, showed some benefits, C/EBPβ overexpression demonstrated a more potent effect in ameliorating myocardial remodeling and fibrosis. This suggests C/EBPβ might be a superior therapeutic target.
  • Modulation of the RAS Axis: C/EBPβ overexpression shifted the RAS balance towards the beneficial Ang(1-7)/MasR axis by decreasing Ang II and increasing Ang(1-7) levels, while also downregulating pro-fibrotic ACE and AT1R and upregulating MasR.

Key Results

  • Improved Cardiac Function: C/EBPβ overexpression significantly improved left ventricular ejection fraction (LVEF) and fractional shortening (FS), while reducing left ventricular end-diastolic diameter (LVEDd) and posterior wall thickness (LVPWd) in diabetic mice.
  • Reduced Fibrosis: Masson's trichrome staining and quantification of collagen I and III showed a significant reduction in fibrosis in C/EBPβ-overexpressing hearts compared to controls.
  • Suppressed Apoptosis: The Bax/Bcl-2 ratio, an indicator of apoptosis, was significantly decreased in C/EBPβ-overexpressing groups.
  • ACE2 Upregulation: C/EBPβ overexpression led to a marked increase in ACE2 protein levels in both vivo and in vitro studies.
  • RAS Axis Shift: Myocardial Ang II levels were reduced, and Ang(1-7) levels were increased with C/EBPβ overexpression. Conversely, ACE and AT1R protein levels decreased, while MasR levels increased.
  • Valsartan Comparison: While valsartan improved some parameters, C/EBPβ overexpression generally showed more pronounced beneficial effects, particularly in reducing fibrosis and improving cardiac function.

Limitations and Future Work

  • Mechanism of AT2R Regulation: The study observed that C/EBPβ overexpression reduced AT2R expression, which is linked to apoptosis, but the precise mechanism for this regulation was not investigated. Future work could explore this connection.
  • Complete Dependence on ACE2: While the findings strongly suggest ACE2 is a key mediator, the authors acknowledge that they did not comprehensively examine whether the effects of C/EBPβ suppression on fibrosis and apoptosis were completely dependent on ACE2. Further studies are warranted to confirm this complete dependence.
  • Clinical Translation Challenges: The paper notes that ACE2 itself is difficult to use as a clinical drug due to instability. Therefore, identifying factors that induce ACE2 expression or activity, like C/EBPβ, is crucial for therapeutic development.
  • Valsartan's Limitations: The study highlights that valsartan, as an AT1R antagonist, primarily targets the AT1R and doesn't directly affect ACE2 expression, unlike C/EBPβ. This suggests that C/EBPβ's mechanism of action may offer broader benefits in DCM.
  • Novel Therapeutic Target: The study concludes by proposing C/EBPβ as a novel potential therapeutic target for ameliorating cardiac dysfunction and remodeling in DCM patients, emphasizing its potential to be more effective than current ARBs. Further investigation into the precise mechanisms and clinical translation of C/EBPβ modulation is needed.

Summary updated

Abstract

Diabetic cardiomyopathy, a major cardiac complication, contributes to heart remodelling and heart failure. Our previous study discovered that CCAAT/enhancer-binding protein β (C/EBPβ), a transcription factor that belongs to a family of basic leucine zipper transcription factors, interacts with the angiotensin-converting enzyme 2 (ACE2) promoter sequence in other disease models. Here, we aimed to determine the role of C/EBPβ in diabetes and whether ACE2 expression is regulated by C/EBPβ. A type 1 diabetic mouse model was generated by an intraperitoneal injection of streptozotocin. Diabetic mice were injected with a lentivirus expressing either C/EBPβ or sh-C/EBPβ or treated with valsartan after 12 weeks to observe the effects of C/EBPβ. In vitro, cardiac fibroblasts and cardiomyocytes were treated with high glucose (HG) to investigate the anti-fibrosis, anti-apoptosis and regulatory mechanisms of C/EBPβ. C/EBPβ expression was down-regulated in diabetic mice and HG-induced cardiac neonatal cells. C/EBPβ overexpression significantly attenuated collagen deposition and cardiomyocyte apoptosis by up-regulating ACE2 expression. The molecular mechanism involved the binding of C/EBPβ to the ACE2 promoter sequence. Although valsartan, a classic angiotensin receptor blocker, relieved diabetic complications, the up-regulation of ACE2 expression by C/EBPβ overexpression may exert greater beneficial effects on patients with diabetic cardiomyopathy.
BibTeX
@article{tie2017scp,
  author = {Yuanyuan Tie and Chungang Zhai and Ya Zhang and Xiaoteng Qin and Fangpu Yu and Hongxuan Li and Meirong Shan and Cheng Zhang},
  title = {{<scp>CCAAT</scp>/enhancer‐binding protein β overexpression alleviates myocardial remodelling by regulating angiotensin‐converting enzyme‐2 expression in diabetes}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2017},
  doi = {10.1111/jcmm.13406},
}
Figure